Literature DB >> 23223655

Hypertriglyceridaemia-induced pancreatitis: a contributory role of capecitabine?

H Y Chan1, C M Ng, S C Tiu, Angel O K Chan, C C Shek.   

Abstract

Capecitabine is an orally administered pro-drug of 5-fluorouracil that confers superior disease-free survival and presumably has a more favourable side-effect profile. Here we report on a patient who developed acute necrotising pancreatitis and very high triglyceride levels as well as hand-foot syndrome after receiving capecitabine for colonic cancer. Increased awareness of this potential side-effect and close monitoring of lipid levels may be warranted, especially in patients who have other conditions predisposing them to severe secondary hyperlipidaemia when using this drug.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23223655

Source DB:  PubMed          Journal:  Hong Kong Med J        ISSN: 1024-2708            Impact factor:   2.227


  4 in total

1.  Chemotherapy-induced fulminant acute pancreatitis in pancreatic carcinoma: A case report.

Authors:  Linghui Lu; Yanni Lou; Huangying Tan
Journal:  Oncol Lett       Date:  2014-07-04       Impact factor: 2.967

2.  Drug induced pancreatitis: A systematic review of case reports to determine potential drug associations.

Authors:  Dianna Wolfe; Salmaan Kanji; Fatemeh Yazdi; Pauline Barbeau; Danielle Rice; Andrew Beck; Claire Butler; Leila Esmaeilisaraji; Becky Skidmore; David Moher; Brian Hutton
Journal:  PLoS One       Date:  2020-04-17       Impact factor: 3.240

3.  Capecitabine-induced hypertriglyceridemia: a rare but clinically relevant treatment-related adverse event.

Authors:  An Uche; Ritika Vankina; Jun Gong; May Cho; James J Yeh; Phyllis Kim; Kathy Pan
Journal:  J Gastrointest Oncol       Date:  2018-12

4.  Lethal cardiotoxicity, steatohepatitis, chronic pancreatitis, and acute enteritis induced by capecitabine and oxaliplatin in a 36-year-old woman.

Authors:  Simona Gurzu; Ioan Jung; Maria Comsulea; Zoltan Kadar; Leonard Azamfirei; Calin Molnar
Journal:  Diagn Pathol       Date:  2013-09-16       Impact factor: 2.644

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.